Hiroyoshi Doihara
   Department   Kawasaki Medical School  Kawasaki Medical School, Department of General Surgery,
   Position   Professor with Special Assignment
Article types 原著
Language English
Peer review Peer reviewed
Title Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers.
Journal Formal name：Oncotarget
Abbreviation：Oncotarget
ISSN code：19492553/19492553
Domestic / ForeginForegin
Volume, Issue, Page 8(16),pp.26122-26128
Author and coauthor Iwamoto Takayuki, Katagiri Toyomasa, Niikura Naoki, Miyoshi Yuichiro, Kochi Mariko, Nogami Tomohiro, Shien Tadahiko, Motoki Takayuki, Taira Naruto, Omori Masako, Tokuda Yutaka, Fujiwara Toshiyoshi, Doihara Hiroyoshi, Gyorffy Balazs, Matsuoka Junji
Publication date 2017/04
Summary BACKGROUND:The purpose of this study was to test whether immunohistochemical (IHC) Ki67 levels after short-term preoperative hormone therapy (post-Ki67) predict similar numbers of patients with favorable prognoses as genomic markers.RESULTS:Thirty paired cases (60 samples) were enrolled in this study. Post-Ki67 levels were significantly lower than pre-treatment Ki67 levels (P < 0.001). Post-Ki67 predicted more low-risk cases (83.3%, 25/30) than pre-genomic surrogate signature(GSS) (66.7%: 20/30), but the difference in predictive power was not significant (P = 0.233). Proliferation (MKI67, STK15, Survivin, CCNB1, and MYBL2) and estrogen (ER, PGR, BCL2, and SCUBE2) related signatures were significantly downregulated after therapy (P < 0.001 and 0.041, respectively).MATERIALS AND METHODS:Core needle biopsy specimens of primary breast cancer were collected at Okayama University Hospital from hormone receptor-positive and human epidermal growth factor 2-negative patients that subsequently received two weeks of neoadjuvant hormone therapy. Paired post-treatment specimens from surgical samples were also collected. IHC Ki67 levels and GSS were compared between pre- and post-hormone treatment samples. Changes of gene expression pattern in short-term hormone therapy were also assessed.CONCLUSIONS:IHC based post-Ki67 levels may have distinct predictive power compared with the naïve IHC Ki67. Future studies with larger cohorts and longer follow-up periods may be needed to validate our results.
DOI 10.18632/oncotarget.15385
PMID 28412725